IQWiG’s First Cost-Effectiveness Review Could Take Drug HTA To New Frontiers
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s reimbursement watchdog IQWiG’s first cost-effectiveness analysis uses four antidepressants as test case and finds they are overpriced.